Connect with us

Biotechnology

Healthcare Penny Stocks To Watch: Driven Deliveries Inc. (DRVD), Biocept Inc. (BIOC), Cesca Therapeutics Inc. (KOOL), PhaseBio Pharmaceuticals Inc. (PHAS)

Joe Samuel

Published

on

Healthcare penny stocks tend to be the largest movers among other penny stocks. This is mainly due to the amount of news they release. For example, any development in treatment becomes a news catalyst, which happens more often than other news.

Driven Deliveries Inc. (DRVD)

Driven Deliveries Inc. (DRVD) is primarily a technology company so why include it with other healthcare penny stocks? It is included because of what Driven’s technology is capable of, delivering medical and recreational marijuana. Medical marijuana legality is sweeping across the US which is only expanding the future demand for the services Driven provides.

More studies are beginning to show the positive effects of marijuana in relation to stress and pain relief. These studies make Driven’s recent announcement way more important. Driven revealed a partnership with Pure Ratios, a company selling 96-hour pain relief CBD and THC patches. This product is the only of its kind as it bypasses the digestive process and is absorbed directly into the bloodstream.

[REPORT] One of the Only Public Cannabis Delivery Services in the United States…Here’s What To Know

Christian Schenk, CEO of Driven, stated, “We believe that our best-in-class delivery platform coupled with Pure Ratio’s proven popular brands will provide a strong synergistic relationship between the companies.  We look forward to expanding our customer base while increasing revenue and enhancing our overall brand recognition.  Management has already identified several similar popular brands that it intends to add to our platform in the near future.”

Biocept Inc (BIOC)

Biocept Inc (BIOC) is a healthcare company that uses liquid biopsy technology to assess several forms of cancer for physicians. Biocept has their own liquid biopsy platform known as Target SelectorTM which can analyze tumor markers.

Recently, Biocept announced a new Target SelectorTM platform for breast cancer. It is Biocept’s second tumor-specific panel and will help target the second leading cause of death for women. In addition, Biocept’s platform allows medical personnel to evaluate patients with metastatic breast cancer which is usually very difficult. This news has brought strong volume and a 11% pre-market move.

Cesca Therapeutics Inc. (KOOL)

Cesca Therapeutics Inc. (KOOL) is a medical device healthcare company for cell-based therapeutics. Cesca is an affiliate of the BoyaLife Group which is based out of China. Cesca is using its AutoXpress platform to meet the needs regarding cardio, vascular, and immune diseases.

One of Cesca’s subsidiaries, ThermoGenesis, recently received approval for its Next-Gen AXP II System for cord blood processing. The AXP II System allows for the processing and storage of hematopoietic stem call concentrates. Also, multiple cord blood units can be processed in one centrifuge. Thanks to this approval, Cesca’s stock increased by more than 40%.

PhaseBio Pharmaceuticals Inc. (PHAS)

PhaseBio Pharmaceuticals Inc. (PHAS) is a biopharmaceutical company whose primary goal is creating and selling treatments to orphan diseases. Their primary drug is called PB2452 which reverses antiplatelet activity. PB2452 recently received positive preliminary results from Phase 2a clinical trial. These results pushed the stock from $12.19 to $14.08 on June 18th.

“If approved, PB2452 could help address these critical unmet medical needs by enhancing the safety profile of ticagrelor, which has the potential to become the only antiplatelet therapy on the market with a specific reversal agent. We look forward to reporting full results from the Phase 2a trial at an upcoming medical congress.”

John Lee, M.D., Ph.D., Chief Medical Officer of PhaseBio

stock_price_weed
Disclaimer: Pursuant to an agreement between MIDAM VENTURES, LLC and a third party, Data Marketing Solutions Inc., Midam was hired for a period from 04/22/2018 – 5/22/2019 to publicly disseminate information about Driven Deliveries Inc. including on the Website and other media including Facebook and Twitter. We were paid $50,000 (CASH) for & were paid “0” shares of restricted common shares. We may buy or sell additional shares of Driven Deliveries Inc. Inc. in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. Click Here For Full Disclaimer

Continue Reading
Click to comment

Biotechnology

3 Biotech Stocks To Watch After Big News This Month

Joe Samuel

Published

on

If there is one sector that has grown immensely strong over the past decade and a half, then it’s biotech. These biotech stocks and underlying companies have come up with highly innovative solutions to a range of diseases. Furthermore, it has been through the use of technology and knowledge of pharmaceuticals, which has added to the innovation.

As a consequence, the sector has grown considerably and a lot of investor capital has flooded into the sector. However, in order to make a return on investment, an investor needs to keep a close eye on the market and then make his investments after he has made a list of the biotech stocks to invest in. On that note, here is a look at 3 biotechnology stocks that proved to be winners recently.

Biotech Stock #1:
PharmaCyte Biotech

PharmaCyte Biotech (PMCB Stock Report) recently announced the appointment of David A. Judd to PharmaCyte’s Medical and Scientific Advisory Board. Mr. Judd has had over 30 years of experience in the research and development of cell culture materials and methods for the culturing various types of human cells. Judd also works at Grand Island Biotechnology Company and is involved in research, process development and cGMP production of biotechnology and cell therapy processes. This could make a perfect fit for him at PharmaCyte.

biotech stocks to buy

If you’re looking at PharmaCyte Biotech at this exact moment, you’re seeing it before the company begins clinical trials and just as it’s preparing to complete its Investigational New Drug Application for the FDA. Whether you’re new to biotech stocks or a seasoned vet, you should understand how important milestones like this are for a company. At this point, PharmaCyte is focused on developing targeted cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box.

Here’s why an open IND is key to PharmaCyte (PMCB) realizing a number of benefits that include:

  • Beginning the formal arrangements required to conduct its clinical trial in LAPC.
  • Working towards the major milestone of enrolling the first patient in its clinical trial.
  • Publishing that the technology behind its LAPC treatment has passed the incredibly difficult FDA screening process and met all of the FDA’s regulatory requirements.
  • Building global exposure of PharmaCyte’s Cell-in-a-Box® technology.
  • Paving the way for the development of treatments for multiple diseases including diabetes and a host of solid tumors. 

Biotech Stock #2:
Provention Bio

The next one to look at is Provention Bio Inc (PRVB Stock Report). The biotech stock has been on a hugely impressive rally this year so far. The biotech stock price has surged by as much as 550% in 2019. Why? The big trigger was the results of a National Institute of Health study into the PRV-031 medicine that was published last month.

The study found significant insight in the company’s PRV-031 medicine. If it’s administered over the course of two weeks, the onset of Type 1 diabetes can be delayed by as long as two years. This was found in patients who are at high risk.

PRVB biotech stock price

Additionally, Provention had started a Phase 3 clinical study of the PRV-031 product back in April. That proved to be an important trigger as well. Enrollment for the Phase 2 study of its Crohn’s disease medicine PRV-6527 has also been concluded.

Biotech Stock #3:
ArQule

The other biotech stock to watch had an excellent run in June. The clinical-stage pharmaceutical firm ArQule, Inc. (ARQL Stock Report) stock jumped as much as 53% over the course of last month.

best-biotech-stocks-ARQL-Arqule-stock

This was due to highly promising data from two clinical trials of its product ARQ 531. The trials showed that its medicine had an effect on cancer variants that affect the white blood cells. The biotech stock also managed to raise substantial capital through a private offering. Moreover, the stock is up 280% since the beginning of this year.

biotech stocks to watch
Disclaimer: Pursuant to an agreement between MIDAM VENTURES, LLC and Complete Investment And Management LLC, a Non-affiliate Third Party, Midam was hired for a period from 07/09/2019 – 8/09/2019 to publicly disseminate information about PharmaCyte Biotech including on the Website and other media including Facebook and Twitter. We were paid $150,000 (CASH) for & were paid “0” shares of restricted common shares. We may buy or sell additional shares of PharmaCyte Biotech in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. Click Here For Full Disclaimer

Continue Reading

Biotechnology

PharmaCyte Biotech (PMCB) Appoints Cellular Expert to Medical and Scientific Advisory Board

Joe Samuel

Published

on

biotech penny stocks to buy

LAGUNA HILLS, Calif.–(BUSINESS WIRE)–PharmaCyte Biotech, Inc. (PMCB), a clinical stage biotechnology company focused on developing targeted cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that it has appointed David A. Judd to PharmaCyte’s Medical and Scientific Advisory Board. Mr. Judd has had over 30 years of experience in the research and development of cell culture materials and methods for the culturing various types of human cells. Most importantly, Mr. Judd has worked for many years with the cells that PharmaCyte uses in its treatment of cancer and has a wealth of knowledge regarding their growth properties.


[Free Report] The Future Of Drug Delivery Has Biotech Investors Focusing On One Small Company


PharmaCyte’s Chief Executive Officer, Kenneth L. Waggoner, stated, “We feel the appointment of Mr. Judd to our Medical and Scientific Advisory Board comes at a crucial time as we work with our colleagues at Austrianova to conduct the final manufacturing runs to produce successfully the encapsulated cells that are needed for our clinical trial in locally advanced, non-metastatic, pancreatic cancer.”

Mr. Waggoner continued, “Mr. Judd was so intrigued by the possibility that our platform technology may change the way many solid tumors are treated, with little to no chemotherapy side effects, that he volunteered to work with us months ago. He has made significant contributions to our efforts in working with Austrianova to ensure that the cells from our Master Cell Bank grow as they should, both pre and post-encapsulation. During a critical time in realigning certain aspects of the manufacturing process, Mr. Judd accompanied us as an advisor to Austrianova’s cGMP manufacturing facility in Bangkok, Thailand, where the encapsulation of our cells is taking place.

“In a recent video interview, which can be viewed at www.PharmaCyte.com/Media, I spoke to why we selected Mr. Judd to join our team and the contributions he has already made to our Cancer Program. We believe that Mr. Judd’s talents and expertise will be invaluable in the development of cellular therapies for cancer as well as our efforts in the development of cellular therapies for diabetes.”

Mr. Judd is a graduate of the Biotechnology program at Rochester Institute of Technology, the first Biotechnology program in the United States. He has over 30 years of experience in cell culture and biochemistry in research and in a cGMP environment. Also, he has extensive experience in research and development of cell culture medium, both in the upstream and downstream processes.

Mr. Judd is currently employed by the Grand Island Biotechnology Company (Gibco) and is involved in research, process development and cGMP production of biotechnology and cell therapy processes.

Mr. Judd has been employed by Gibco (now owned by ThermoFischer Scientific) for 29 years and is a co-inventor on 5 patents involving cell culture materials.

About PharmaCyte Biotech:

PharmaCyte Biotech is a clinical stage biotechnology company developing cellular therapies for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as “Cell-in-a-Box®.” This technology will be used as a platform upon which therapies for several types of cancer and diabetes are being developed.

PharmaCyte’s therapy for cancer involves encapsulating genetically engineered human cells that convert an inactive chemotherapy drug into its active or “cancer-killing” form. For pancreatic cancer, these encapsulated cells are implanted in the blood supply to the patient’s tumor as close as possible to the site of the tumor. Once implanted, a chemotherapy drug that is normally activated in the liver (ifosfamide) is given intravenously at one-third the normal dose. The ifosfamide is carried by the circulatory system to where the encapsulated cells have been implanted. When the ifosfamide flows through pores in the capsules, the live cells inside act as a “bio-artificial liver” and activate the chemotherapy drug at the site of the cancer. This “targeted chemotherapy” has proven effective and safe to use in past clinical trials and results in little to no treatment related side effects.

PharmaCyte’s therapy for Type 1 diabetes and insulin-dependent Type 2 diabetes involves encapsulating a human cell line that has been genetically engineered to produce, store and release insulin in response to the levels of blood sugar in the human body. PharmaCyte is exploring the use of genetically modified liver cells, stem cells and beta islet cells. The encapsulation will be done using the Cell-in-a-Box® technology. Once the encapsulated cells are implanted in a diabetic patient, they will function as a “bio-artificial pancreas” for purposes of insulin production.

Safe Harbor

This press release contains forward-looking statements, which are generally statements that are not historical facts. Forward-looking statements can be identified by the words “expects,” “anticipates,” “believes,” “intends,” “estimates,” “plans,” “will,” “outlook” and similar expressions. Forward-looking statements are based on management’s current plans, estimates, assumptions and projections, and speak only as of the date they are made. We undertake no obligation to update any forward-looking statement because of new information or future events, except as otherwise required by law. Forward-looking statements involve inherent risks and uncertainties, most of which are difficult to predict and are generally beyond our control. Actual results or outcomes may differ materially from those implied by the forward-looking statements due to the impact of numerous risk factors, many of which are discussed in more detail in our Annual Report on Form 10-K and our other reports filed with the Securities and Exchange Commission.

More information about PharmaCyte Biotech can be found at www.PharmaCyte.com. Information may also be obtained by contacting PharmaCyte’s Investor Relations Department.

Continue Reading

Biotechnology

List Of Biotech Stocks To Watch This Quarter

A. Lawrence

Published

on

biotech stock price

Biotech has been one of the hottest sectors for the past few years. Much of that is due to the fact that there are many biotech stocks doing highly innovative work.

Even in the present day, it is a sector that has thrown up plenty of winners for investors and hence, it is a sector that should be watched closely in order to decide on an investment. Here is a look at three big biotech stock gainers in the space in 2019.

Biotech Stock To Watch #1: Blueprint Medicines

One of the biggest biotech gainers this year so far has been Blueprint Medicines Corp (NASDAQ:BPMC). BPMC stock price has gained as much as 90% in 2019 so far. Much of the optimism is grounded in fairly positive news with regards to the company’s core business. Blueprint creates targeted therapies for cancer. The company had announced this year that following considerable success in the clinical trials one of its products had filed for a new drug application.

The name of the medicine is avapritinib and it is supposed to stop the growth of tumors. It’s an important development. The reason: for many years such medicine had not been in the market. If it gets approved then it would be a huge achievement for the company.

Biotech Stock To Watch #2: PharmaCyte Biotech

Timing is always important, especially when dealing with the stock market.  What may be more crucial is when we’re talking about the biotech sector. Whether it’s phase trials or things like an investigational new drug designation, events like this could act as catalysts for companies.

Here’s why an open IND is key to PharmaCyte (PMCB) realizing a number of benefits that include:

  • Beginning the formal arrangements required to conduct its clinical trial in LAPC.
  • Working towards the major milestone of enrolling the first patient in its clinical trial.
  • Publishing that the technology behind its LAPC treatment has passed the incredibly difficult FDA screening process and met all of the FDA’s regulatory requirements.
  • Building global exposure of PharmaCyte’s Cell-in-a-Box® technology.
  • Paving the way for the development of treatments for multiple diseases including diabetes and a host of solid tumors. 

But aside from this, timing is so important right now because an approved IND submission would mean clinical trials could begin 30 calendar days from the submission date of the IND!

The best part:  the data obtained to date from the encapsulation parameters of the manufacturing process itself indicate that the encapsulation portion of the process is fault free and reproducible, which is a fundamental requirement of the FDA.

Could those looking at PharmaCyte Biotech (PMCB) at this exact moment be looking at a “right place/right time scenario?”  

Biotech Stock To Watch #3: Array Biopharma

The other biotech stock that has gained as much as Blueprint is that of Array Biopharma Inc (NASDAQ:ARRY). It’s an important factor since Array is also involved in developing targeted cancer treatments. The company’s success lies in its two medicines, Braftovi and Mektovi, which are meant for the treatment of melanoma.

The medicines had been licensed by Novartis. Once the medicines were returned, Array received an excellent acquisition offer from pharma giant Pfizer. The deal is going to see Pfizer shell out $11.1 billion to acquire the company. Following that development, ARRY stock price soared by as much as 75% in June alone. The stock is up a whopping 213% so far in 2019.

stock market news june
Disclaimer: Pursuant to an agreement between MIDAM VENTURES, LLC and Complete Investment And Management LLC, a Non-affiliate Third Party, Midam was hired for a period from 07/09/2019 – 8/09/2019 to publicly disseminate information about PharmaCyte Biotech including on the Website and other media including Facebook and Twitter. We were paid $150,000 (CASH) for & were paid “0” shares of restricted common shares. We may buy or sell additional shares of PharmaCyte Biotech in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. Click Here For Full Disclaimer

Continue Reading

Join Our Newsletter

Get stock alerts, news & trending stock alerts straight to your inbox!


We keep all user information pricate & promise to never spam.*

Privacy Policy

Search Stock Price (StockPrice.com)




Trending

Subscribe Now & Begin Receiving Free Stocks News, Articles, Trade Alerts & MORE, all 100% FREE!

We are your #1 source for all things Stock Market & Finance, Subscribe Below!

Privacy Policy: We will NEVER share, sell, barter, etc. any of our subscribers information for any reason ever! By subscribing you agree we can send you via email our free e-newsletter on stock market & finance related, articles, news and trade alerts. Further questions please contact privacy@stockprice.com